Home
About Us
Company Overview
Innovation and Leadership
Products
Discovery
Company Highlights
Company History
Our People
Senior Management
Our Reach
Awards and Recognition
Australian Industry Participation Purchasing Policy
Positions Vacant
Legal Disclaimer
Our Products
Aridol
Current clinical trials
Aridol Distributors
Bronchitol
Current clinical trials
Bronchitol Distributors
Respiratory Diseases
Named Patient Program (Compassionate Use)
Scientific Publications
Patents
Investors
ASX Announcements
ASX 2012
ASX 2011
ASX 2010
ASX 2009
ASX 2008
ASX 2007
ASX 2006
ASX 2005
ASX 2004
ASX 2003
News
Quarterly Reports
Annual Reports
Investor Presentations
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Share Price
Shareholder Services
Join Our Mailing List
Contact Us
Events Calendar
Financial Summary
Analyst Coverage
Shareholders
Corporate Directory
Corporate Governance
SEC Filings
Pharmaxis ADRs
News
Media Releases
Media 2012
Media 2011
Media 2010
Media 2009
Media 2008
Media 2007
Media 2006
Media 2005
Media 2004
Media 2003
Quarterly Reports
Quarterly Reports 2012
Quarterly Reports 2011
Quarterly Reports 2010
Quarterly Reports 2009
Quarterly Reports 2008
Quarterly Reports 2007
Quarterly Reports 2006
Quarterly Reports 2005
Quarterly Reports 2004
Media Contact
News Feeds
New Product Pipeline
Clinical Trials
Scientific Publications
Investigator-Initiated Studies
Respiratory diseases
Patents
Contact Us
Health Professionals
Patients
Media Releases
Quarterly Reports
Media Contact
News Feeds
Pharmaxis
Home
News
Media Releases
Media 2009
Media Releases
MEDIA RELEASES
29.12.2009 - Pharmaxis receives response letter from the FDA on Aridol application
16.12.2009 - Pharmaxis lodges TGA application to market Bronchitol™ for CF in Australia
02.12.2009 - Pharmaxis Announces Sustained Benefit with Bronchitol in Phase 3 Cystic Fibrosis Trial
23.11.2009 - FDA Advisory Committee Recommends Approval of Aridol
29.10.2009 - Pharmaxis Applies to Market Bronchitol for Cystic Fibrosis in Europe
23.10.2009 - Pharmaxis Commences Pivotal Bronchiectasis Study and Aligns Global Registration Strategy
21.10.2009 - Chairman's Address to AGM
15.10.2009 - Recording of Investor Conference Call - 15 October 2009
13.10.2009 - Conference Call Details - Quarterly Report to Shareholders and Investor Conference Call
18.09.2009 - Second Cystic Fibrosis Trial Passes Recruitment Target
11.09.2009 - Pharmaxis to Present at European Respiratory Society Meeting
23.07.2009 - Recording of Investor Conference Call - 23 July 2009
21.07.2009 - Conference Call Details - Quarterly Report to Shareholders and Investor Conference Call
13.07.2009 - Pharmaxis to Voluntarily De-List from Nasdaq
30.06.2009 - Pharmaxis Closes Share Purchase Plan
16.06.2009 - Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
04.06.2009 - Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
14.05.2009 - US FDA Accepts Aridol New Drug Application for Review
05.05.2009 - Conference Call Access
04.05.2009 - Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
17.04.2009 - Investor Conference Call Recording
07.04.2009 - New Pharmaxis Board Appointment: Richard van den Broek
06.04.2009 - Quarterly Report to Shareholders and Investor Conference Call
01.04.2009 - Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
11.03.2009 - Pharmaxis Appoints French Distributor for Aridol
02.03.2009 - Pharmaxis Submits New Drug Application for Aridol to FDA
17.02.2009 - Pharmaxis Builds Senior Management Team
29.01.2009 - Investor Conference Call Recording
27.01.2009 - Investor Conference Call
Category:
All
ASX 2009
ASX 2010
ASX 2011
ASX 2012
Home
Investor 2009
Investor 2010
Investor 2011
Media 2010
Media 2011
Media 2012
News and Media
Quarterly 2009
Quarterly 2010
Quarterly 2011
Quarterly 2012
Media 2009
ASX Announcements
Investor Presentations
Quarterly Reports
Sec Filings
Annual
PAGE CONTENTS
Media 2012
Media 2011
Media 2010
Media 2009
Media 2008
Media 2007
Media 2006
Media 2005
Media 2004
Media 2003